In an effort to inform the public of health risks and the spread of outbreaks, Metabiota has launched a free "epidemic follower" to track global illnesses. The drug pathogen Candida auris, which is drug-resistant, has contributed to the release of this tool.
Bill Rossi, Metabiota's CEO, said in a statement that "there is no effective way that (health) organizations can plan and mobilize against emerging health threats."
Rossi, as an example of the spread of the Zika virus, which is transmitted by mosquitoes mainly in tropical and subtropical areas, currently lacks effective vaccination. related epidemics also have an economic effect in respect of the costs of treatment and research or in the sectors related to tourism.
Metabiota's goal is to make the world more resistant to health threats by providing an open, focused and balanced insight into emerging and ongoing outbreaks. It should be noted that as a common source of data, the site is sufficient, but the tool does not provide the level of detail that would allow users to make informed decisions.
"This digital platform is open to anyone who wants to learn more about current epidemics that can have a global impact," said Metabiota manager Ben Oppenheim. There is also a paid premium version, including patterns of pathogens and indexes for more advanced analysis and risk analysis.
Epidemic Tracker says, "Epidemics of infectious diseases can cause huge damage." Recent events like SARS, MERS, and Zika have led to significant human health consequences, as well as billions of dollars in economic losses.
The World Economic Forum believes in this pandemics can cause a global loss of $ 570 billion a year, The site aims to provide the opportunity to review, analyze and understand events that may affect people, industries and entire nations.
It should be noted that the service provided met mixed reception. For example, according to TechCrunch, the curiosity of users who are interested in the emergence of various diseases can satisfy. Overall, however, the project considers "the way the company is trying to take advantage of paranoia about health risks."